Renaissance Technologies LLC Sells 23,300 Shares of Celcuity Inc. (NASDAQ:CELC)

Renaissance Technologies LLC lowered its stake in Celcuity Inc. (NASDAQ:CELC) by 31.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 51,556 shares of the company’s stock after selling 23,300 shares during the quarter. Renaissance Technologies LLC owned approximately 0.15% of Celcuity worth $844,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in Celcuity in the 4th quarter valued at $21,583,000. Commodore Capital LP raised its holdings in Celcuity by 3.6% during the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after purchasing an additional 60,563 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Celcuity in the first quarter valued at $3,545,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Celcuity during the 2nd quarter valued at about $888,000. Finally, BNP Paribas Financial Markets grew its position in shares of Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after buying an additional 3,930 shares during the period. 63.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CELC shares. Lifesci Capital assumed coverage on shares of Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective on the stock. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Finally, Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Celcuity currently has a consensus rating of “Buy” and an average price target of $29.17.

Celcuity Stock Up 1.5 %

Celcuity stock opened at $15.27 on Tuesday. The stock has a fifty day moving average of $15.84 and a 200 day moving average of $16.62. Celcuity Inc. has a one year low of $8.39 and a one year high of $22.19. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95. The stock has a market cap of $535.99 million, a PE ratio of -5.49 and a beta of 0.75.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the previous year, the company posted ($0.66) earnings per share. As a group, sell-side analysts predict that Celcuity Inc. will post -2.54 EPS for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.